Teva Branded Pharmaceutical Products R&D LLC — Biomedical Watch V2

Traitements8programmes

Essais7liés

Publications3liées

SourceDBlocale

Traitements

8

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
FremanezumabThe goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks. Participants diagnosed with episodic or chronic migraine with menstrually-related migraine with or without aura and treated with fremanzumab according to the SmPC will be required to maintain a headache diary over at least 3 months prior to and 6 months after fremanezumab initiation.	Migraine	Phase 3	À vérifier	United States, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, …	À vérifier
FremanezumabThe goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks. Participants diagnosed with episodic or chronic migraine with menstrually-related migraine with or without aura and treated with fremanzumab according to the SmPC will be required to maintain a headache diary over at least 3 months prior to and 6 months after fremanezumab initiation.	Migraine	À vérifier	À vérifier	Switzerland	À vérifier
FremanezumabThe goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks. Participants diagnosed with episodic or chronic migraine with menstrually-related migraine with or without aura and treated with fremanzumab according to the SmPC will be required to maintain a headache diary over at least 3 months prior to and 6 months after fremanezumab initiation.	Migraine	À vérifier	À vérifier		À vérifier
FremanezumabThe goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks. Participants diagnosed with episodic or chronic migraine with menstrually-related migraine with or without aura and treated with fremanzumab according to the SmPC will be required to maintain a headache diary over at least 3 months prior to and 6 months after fremanezumab initiation.	Migraine	Phase 3	À vérifier	United States, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain	À vérifier
FremanezumabThe goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks. Participants diagnosed with episodic or chronic migraine with menstrually-related migraine with or without aura and treated with fremanzumab according to the SmPC will be required to maintain a headache diary over at least 3 months prior to and 6 months after fremanezumab initiation.	Migraine	Phase 3	À vérifier	United States, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain	À vérifier
FremanezumabThe goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks. Participants diagnosed with episodic or chronic migraine with menstrually-related migraine with or without aura and treated with fremanzumab according to the SmPC will be required to maintain a headache diary over at least 3 months prior to and 6 months after fremanezumab initiation.	Migraine	Phase 3	À vérifier	United States, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain	À vérifier
FremanezumabThe goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks. Participants diagnosed with episodic or chronic migraine with menstrually-related migraine with or without aura and treated with fremanzumab according to the SmPC will be required to maintain a headache diary over at least 3 months prior to and 6 months after fremanezumab initiation.	Migraine	Phase 4	À vérifier	United States	À vérifier
FremanezumabThe goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks. Participants diagnosed with episodic or chronic migraine with menstrually-related migraine with or without aura and treated with fremanzumab according to the SmPC will be required to maintain a headache diary over at least 3 months prior to and 6 months after fremanezumab initiation.	Migraine	À vérifier	Traitement symptomatique	Italy	À vérifier

Essais cliniques

7

Molécule	Indication / population	Phase	NCT	Titre	Statut
Fremanezumab	Migraine	À vérifier	NCT07029126	Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity	COMPLETED
Fremanezumab	Migraine	Phase 4	NCT06173661	Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45	COMPLETED
Fremanezumab	Migraine	Phase 3	NCT04464707	A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age	COMPLETED
Fremanezumab	Migraine	Phase 3	NCT04458857	A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age	COMPLETED
Fremanezumab	Migraine	Phase 3	NCT04530110	A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents	COMPLETED
Fremanezumab	Migraine	À vérifier	NCT03539393	Fremanezumab Managed Access Program for Pediatric Patients	AVAILABLE
Fremanezumab	Migraine	À vérifier	NCT06659120	FROMM — Fremanezumab for the Prevention of Menstrually-related Migraine Attacks	RECRUITING

Publications

3

Molécule	Indication / population	Titre	Journal	Date
Fremanezumab		Real-World Characteristics and Treatment Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Users: a Japanese Claims Database-Based Study.	Pain and therapy
Fremanezumab		Expanding preventive options for pediatric migraine: the use of anti-CGRP monoclonal antibodies for children and adolescents with migraine.	Translational pediatrics
Fremanezumab		Tumor expression of CGRP confers sensitivity to growth inhibition by the anti-CGRP antibody fremanezumab.	European journal of pharmacology